RxDoctor Payments Data

James McConnell, MD

Internal Medicine · Wytheville, VANPI 1326027012

Payments from drug & device makers

$1,667in general payments, 2019–2025

Across 91 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$594
  • Johnson & Johnson$200
  • Novo Nordisk$159
  • Biodelivery Sciences International, Inc.$149
  • Exact Sciences$117
  • Cardinal Health 200 LLC$114
  • plus $335 from 7 others

What the payments were for

  • Food & beverage$1,57695%
  • Education$915%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,667 in reported general payments places this provider in the 80th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$92,219
Medicare patients
139
Services billed
764

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide85$105,908
EliquisApixaban87$90,600
Breztri AerosphereBudesonide/Glycopyr/Formoterol70$70,808
Tresiba Flextouch U-200Insulin Degludec41$53,367
FarxigaDapagliflozin Propanediol42$46,174
XareltoRivaroxaban35$36,769
JanuviaSitagliptin Phosphate23$34,910
NucyntaTapentadol Hcl11$22,204
RybelsusSemaglutide15$21,699
LinzessLinaclotide14$17,955
OxycontinOxycodone Hcl25$17,798
JardianceEmpagliflozin24$14,179
EntrestoSacubitril/Valsartan19$12,583
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$11,835
Lantus SolostarInsulin Glargine,hum.Rec.Anlog53$11,577

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$159$127,607100 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$594$124,566129 claims
PfizerEliquis$82$90,60087 claims
Johnson & JohnsonXarelto$200$36,76935 claims
AbbVieLinzess, Synthroid$105$20,29644 claims
Boehringer IngelheimJardiance$73$14,17924 claims
GSKTrelegy Ellipta$20$11,83514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Wytheville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →